Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | CHKA | P35790 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2881359 | 0.80 | CYP4F2 (0.35) | TLR7 | |
| SCHEMBL6225770 | 0.75 | ALDH1A1 (0.63) | ALDH1A1HTTSMN1; SMN2KDM4EDPP4 | |
| SCHEMBL26351812 | 0.74 | ALDH1A1 (0.62) | ALDH1A1HTTSMN1; SMN2KDM4ECHKA | |
| SCHEMBL26351817 | 0.74 | ALDH1A1 (0.62) | ALDH1A1HTTSMN1; SMN2KDM4ECHKA | |
| SCHEMBL2881111 | 0.74 | APLNR (0.41) | — | |
| SCHEMBL2876452 | 0.74 | ALDH1A1 (0.61) | ALDH1A1HTTSMN1; SMN2KDM4EDPP4 | |
| SCHEMBL1245422 | 0.70 | TAAR1 (0.44) | — | |
| SCHEMBL28645295 | 0.70 | ALDH1A1 (0.65) | ALDH1A1HTTSMN1; SMN2KDM4EDPP4 | |
| SCHEMBL24206569 | 0.69 | DUT (0.32) | TLR7 | |
| SCHEMBL20160917 | 0.69 | GPR84 (0.35) | SMN1; SMN2DRD4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216758-A1 | Pyridone Compounds | MSD K.K. (JP) | 2010-08-26 | — | — | US | disclosed |
| EP-1916239-A1 | PYRIDONE COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216758-A1 | Pyridone Compounds | NPY1R, MC5R, MC1R | ALDH1A1 1631/4885HTT 3957/4885SMN1; SMN2 4124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.